Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Has Consensus Target Price of $10.33

Posted by Stanley Muller on Oct 25th, 2026

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) has earned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.33.

Several analysts recently issued reports on the stock. HC Wainwright began coverage on shares of Larimar Therapeutics in a research note on Thursday, July 2nd. They set a “buy” rating and a $10.00 price objective for the company. Robert W. Baird decreased their target price on shares of Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 30th. Leerink Partners started coverage on Larimar Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $13.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Finally, Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, June 30th.

Get Our Latest Stock Report on LRMR

Larimar Therapeutics Trading Up 3.5%

Shares of LRMR stock opened at $2.35 on Tuesday. Larimar Therapeutics has a 12-month low of $1.91 and a 12-month high of $6.42. The business’s 50 day moving average is $3.38 and its two-hundred day moving average is $3.72. The company has a market capitalization of $244.12 million, a P/E ratio of -1.21 and a beta of 0.68.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.08. On average, research analysts predict that Larimar Therapeutics will post -1.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Larimar Therapeutics

Several large investors have recently modified their holdings of LRMR. WINTON GROUP Ltd purchased a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at approximately $160,000. Engineers Gate Manager LP purchased a new position in shares of Larimar Therapeutics during the 2nd quarter worth approximately $69,000. Integrated Wealth Concepts LLC purchased a new position in shares of Larimar Therapeutics during the 2nd quarter worth approximately $27,000. Squarepoint Ops LLC acquired a new stake in Larimar Therapeutics in the 2nd quarter valued at approximately $346,000. Finally, Corient Private Wealth LP acquired a new stake in Larimar Therapeutics in the 2nd quarter valued at approximately $69,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases.